SpeciCare
SpeciCare is a US healthcare company that cryopreserves live tumor tissue at -196°C and offers related advanced cancer testing, serving individual cancer patients, clinicians, and research organizations through direct and channel-based sales.
- Company typePrivate
- Founded2015
- HeadquartersGainesville, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
What SpeciCare does
SpeciCare is a privately held US healthcare services company founded in 2015 and headquartered in Gainesville, Georgia, that cryopreserves live tumor tissue at ultra-low temperatures (-196°C in liquid nitrogen) and offers a suite of advanced cancer testing services built on the preserved tissue. The company serves three customer segments: individual cancer patients acquired direct-to-consumer; clinicians (oncologists, surgeons, pathologists) reached via a clinical liaison network and the SpeciCare Cancer Tissue Management Network; and research organizations (pharmaceutical companies, biotech firms, contract research organizations, and academic laboratories) accessed through SpeciBank, a biospecimen licensing sub-brand.
The product architecture is platform-plus-modules. The core platform is tissue cryopreservation and storage using a proprietary SpeciKit collection kit shipped to the patient's surgical team, with specimens transported to an FDA-compliant cryogenic facility at 690 Medical Park Ln, Gainesville, GA. Built atop this core are advanced testing modules including ex-vivo drug sensitivity testing (against 300+ therapies), genomic profiling (DNA/RNA sequencing), immunotherapy biomarker analysis (PD-L1, MMR/MSI, TMB), personalized vaccine pathway support, clinical trial matching, and organoid creation. SpeciBank operates as a separate sub-brand licensing cryopreserved biospecimens under MTAs to research customers, with a searchable database of 498+ entries.
Revenue is generated through four streams: one-time cryopreservation fees of $879 (tissue or bone marrow) or $1,499 (tissue + blood) plus shipping of $149-$499; recurring storage subscriptions at $29/month or $290/year; biospecimen licensing fees via SpeciBank (cost-recovery, study-based, programmatic, and derived-material access); and professional services fees for advanced testing coordination. Go-to-market combines DTC patient acquisition (free 15-minute consultations, Calendly booking, online/phone enrollment) with enterprise sales to clinicians and research institutions. The company has disclosed two funding rounds totaling approximately $3.6M (2016 and 2017) and operates with a lean leadership team of roughly 9-10 named staff.
SpeciCare firmographics
Firmographics- Name
- SpeciCare
- Legal name
- SpeciCare
- Website
- https://specicare.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SpeciCare is a US healthcare company that cryopreserves live tumor tissue at -196°C and offers related advanced cancer testing, serving individual cancer patients, clinicians, and research organizations through direct and channel-based sales.
- Ownership category
- akta.pro rank
SpeciCare industry classification
Industry- Product category
- Cancer Tissue Cryopreservation Services
- NAICS
- Blood and Organ Banks (621991), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ)
Keywords
Where SpeciCare is headquartered
LocationHeadquarters
- HQ city
- Gainesville
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
SpeciCare business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Tissue Cryopreservation Services: One-time fees for cryopreservation of tumor tissue, blood, or bone marrow aspirate using proprietary SpeciKit collection system. Pricing varies by specimen type (tissue only, tissue and blood, or bone marrow). Includes processing and documentation.
- Cryostorage Services: Recurring monthly or annual storage fees for maintaining cryopreserved biospecimens at ultra-low temperatures in FDA-compliant facility. Monthly autopay at $29/month or annual prepayment at $290/year (10 months of storage with 2 months free). Storage includes 4 aliquots; additional aliquots at $5 each.
- Biospecimen Licensing (SpeciBank): Governed access fees for research organizations, pharmaceutical companies, biotech innovators, and university laboratories to license cryopreserved cancer tissue samples. Includes cost-recovery access fees, study-based access, programmatic partnerships, and derived-material access. MTAs and standard contracting mechanisms used.
- Advanced Testing Coordination: Coordination services for advanced testing including treatment effectiveness testing, genomic profiling, immunotherapy biomarker testing, and clinical trial matching. Testing priced separately based on which tests are selected.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Tissue Cryopreservation |
| One time/ perpetual license | Pay-as-you-go | Tissue AND Blood Cryopreservation |
| One time/ perpetual license | Pay-as-you-go | Bone Marrow Aspirate Cryopreservation |
| Subscription | Monthly | Monthly Storage (4 aliquots) |
| Subscription | Annual | Annual Storage (4 aliquots) |
| Unit Pricing | Pay-as-you-go | Additional Aliquots |
| Other | Pay-as-you-go | Standard Shipping |
| Other | Pay-as-you-go | Expedited Shipping |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels10 records
SpeciCare product offering
Product offeringCore offering
SpeciCare provides cryopreservation of live tumor tissue, blood, and bone marrow aspirate at -196°C in liquid nitrogen using its proprietary SpeciKit collection system, maintaining cellular viability and DNA/RNA integrity for decades. On this foundation, the company offers advanced testing coordination including ex-vivo drug sensitivity testing against 300+ therapies, genomic profiling, immunotherapy biomarker analysis, personalized vaccine pathway support, and clinical trial matching. Through its SpeciBank sub-brand, SpeciCare also licenses cryopreserved biospecimens to pharmaceutical companies, contract research organizations, biotech firms, and academic research laboratories for drug development and biomarker discovery.
Product overview
SpeciCare is a cancer tissue cryopreservation and advanced testing services company built on a platform-plus-modules architecture. The core platform is the Tissue Cryopreservation & Storage service, which preserves live tumor tissue at -196°C in liquid nitrogen to maintain cellular viability for future testing. Built on this foundation are advanced testing modules including Treatment Effectiveness Testing (ex-vivo drug sensitivity against 300+ therapies), Genomic Profiling (DNA/RNA sequencing for actionable mutations), Immunotherapy Readiness (biomarker evaluation including PD-L1, MMR/MSI, TMB), Personalized Vaccines (neoantigen-based vaccine pathway support), Clinical Trials Matching, and Organoid Creation (3D tumor model cultivation). The SpeciCare Cancer Tissue Management Network provides clinician-facing infrastructure for workflow standardization and research participation. SpeciBank enables research organizations to license biospecimens. The SpeciKit is a collection kit product for surgical team tissue handling.
Differentiator
Problem solved
Functional benefit
Brands
- SpeciBank: A biospecimen licensing service providing high-quality cancer tissue samples to research organizations, pharmaceutical companies, biotech innovators, and university research laboratories for oncology research, drug development, biomarker discovery, and translational medicine.
Products and services
- Tissue Cryopreservation & Storage Preservation of live tumor tissue, blood, and bone marrow aspirate at ultra-low temperatures (liquid nitrogen at -196°C) for long-term storage, maintaining cellular viability and molecular integrity for future testing, treatment decisions, and clinical trial access. One-time fees range from $879 to $1,499 plus shipping, with recurring storage at $29/month or $290/year.
- SpeciKit Collection System
Quantifiable outcome
- Cryopreserved tissue enables testing against 300+ cancer drugs in ex-vivo sensitivity assays, while standard FFPE tissue cannot support any functional testing
- +3 more outcomes
Companies that use SpeciCare
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
SpeciCare technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
SpeciCare partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights6 records
SpeciCare competitors and assessment
Company assessmentDirect peers
- Champions Oncology: Champions Oncology provides patient-derived xenograft (PDX) tumor models, ex-vivo drug screening, and biospecimen services for oncology research — directly comparable to SpeciCare's SpeciBank biospecimen licensing and ex-vivo drug sensitivity testing offering.
- Crown Bioscience (JSR Life Sciences): Crown Bioscience is a global preclinical CRO offering patient-derived models, biospecimens, and ex-vivo/in-vivo drug response assays — overlapping SpeciCare's research-side value proposition and serving the same pharma/biotech translational customers.
- BioIVT: BioIVT supplies high-quality human biospecimens, including fresh and cryopreserved tissue, to pharmaceutical and academic researchers — a directly analogous biospecimen-licensing business to SpeciBank.
- iSpecimen: iSpecimen operates an online marketplace connecting researchers with human biospecimens from a network of healthcare providers — a comparable model for sourcing and licensing annotated tissue samples to pharma and academic customers.
- Cureline: Cureline is a human biospecimen provider offering fresh, frozen, and FFPE tissue with clinical data to life-science researchers — a directly comparable biospecimen supplier competing for the same SpeciBank customer base.
- Folio Bio (formerly Conversant Bio): Folio Bio provides human tissue samples and biobanking services to pharmaceutical and academic researchers, including cryopreserved specimens with annotated clinical data — a directly comparable biospecimen CRO.
- Tissue Solutions: Tissue Solutions supplies human tissue samples (fresh, frozen, FFPE) and biofluids to pharma and academic researchers with governed MTAs — a closely analogous biospecimen supplier to SpeciBank, primarily operating in Europe.
Broad incumbents
- Tempus: Tempus operates a precision medicine platform combining molecular profiling, biobanking, and AI-driven clinical decision support — overlapping SpeciCare's genomic profiling and clinical-trial matching modules but at vastly larger scale with broader data products.
- Caris Life Sciences: Caris provides molecular profiling and biobanking services across cancer, including tissue-based NGS, with an established pharma research services arm — a broader incumbent operating in adjacent precision-oncology tissue services.
Emerging players
- Personalis: Personalis provides tumor-informed genomic profiling including whole-genome and RNA-based assays for oncology — comparable to SpeciCare's genomic profiling module but focused on the molecular analytics layer rather than cryopreservation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
SpeciCare social profiles
Digital presenceSpeciCare financial estimates
Financial estimateRevenue estimate
Valuation estimate
SpeciCare leadership team
Management profileNumber of profiles
Profiles9 records
SpeciCare funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SpeciCare M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SpeciCare
What does SpeciCare do?
SpeciCare provides cryopreservation of live tumor tissue, blood, and bone marrow aspirate at -196°C in liquid nitrogen using its proprietary SpeciKit collection system, maintaining cellular viability and DNA/RNA integrity for decades. On this foundation, the company offers advanced testing coordination including ex-vivo drug sensitivity testing against 300+ therapies, genomic profiling, immunotherapy biomarker analysis, personalized vaccine pathway support, and clinical trial matching. Through its SpeciBank sub-brand, SpeciCare also licenses cryopreserved biospecimens to pharmaceutical companies, contract research organizations, biotech firms, and academic research laboratories for drug development and biomarker discovery.
Is SpeciCare a public or private company?
SpeciCare is a private company. It is classified as venture growth investor backed and is currently operating.
When was SpeciCare founded?
SpeciCare was founded in 2015. It employs 11 to 50 people.
Where is SpeciCare based?
SpeciCare is headquartered in Gainesville, United States, in the North America region.
How does SpeciCare make money?
Four revenue lines are on record. Tissue Cryopreservation Services are the primary driver. The others are cryostorage Services, biospecimen Licensing (SpeciBank) and advanced Testing Coordination.
Who are SpeciCare's main competitors?
Direct peers on record are Champions Oncology, Crown Bioscience (JSR Life Sciences), BioIVT, iSpecimen, Cureline, Folio Bio (formerly Conversant Bio) and Tissue Solutions. Broad incumbents are Tempus and Caris Life Sciences. Personalis is listed as an emerging player.
Does SpeciCare have an API?
No public API is recorded for SpeciCare.
What industry is SpeciCare in?
SpeciCare's product category is Cancer Tissue Cryopreservation Services. Its primary akta.pro industry code is HLAGAIAJ, Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats). Its NAICS code is 621991 and its SIC code is 8071.